Europe — EMA

Omjjara (Momelotinib)

Momelotinib, the active ingredient in Omjjara, is a drug class presented as a strength/form for oral use. It treats myelofibrosis in adult patients.

Momelotinib

Request sourcing

Pack/s

What is Momelotinib?

Momelotinib, the active ingredient in Omjjara, is a drug class presented as a strength/form for oral use. It treats myelofibrosis in adult patients.

GNH USA supplies Omjjara as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

What is Momelotinib used for?

Omjjara is an oral JAK1/2 inhibitor that focuses on the JAK‑STAT signaling pathway and its role in myelofibrosis. - Myelofibrosis: Improves the symptom burden and reduces spleen size in patients with the d ... ... ... t .... ... t ... ... ... """" … \

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →